Clinical Trial Detail

NCT ID NCT03758781
Title IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung non-small cell carcinoma

melanoma

transitional cell carcinoma

head and neck squamous cell carcinoma

renal cell carcinoma

Therapies

Cyclophosphamide + IRX-2 + Nivolumab

Age Groups: adult senior

No variant requirements are available.